Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Predisposition Biomarkers Market size is expected to register remarkable growth rate during the forecast period i.e., between 2025-2037.
The growth of the market can be attributed to the various advantages provided by biomarkers in reducing and monitoring the risks of several acute and chronic disease, along with aid in diagnosis and treatment. The use of biomarkers, significantly reduces the healthcare expenditure, as it monitors the health beforehand, which is estimated to boost its demand throughout the forecast period. Moreover, the rising prevalence of diseases, such as, cancer, and diabetes along with increasing government initiatives to reduce the cases of such diseases, is anticipated to promote the market growth. According to the data by the WHO, over 422 million people around the world suffer from diabetes, and it causes about 1.6 million deaths every year. Furthermore, introduction of novel and advanced technologies, such as, digital biomarkers, and escalating adoption of personalized medicines is projected to boost the market growth.
Predisposition Biomarkers Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Chronic Diseases, Such as, Cancer, and Diabetes
- Advancement in Diagnostic Technology
- Ease of Availability and Use of Biomarkers
Challenges
- Lack of Efficient Healthcare System in Developing Countries
Predisposition Biomarkers Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
#N/A |
|
Base Year Market Size (2024) |
#N/A |
|
Forecast Year Market Size (2037) |
#N/A |
|
Regional Scope |
|
Predisposition Biomarkers Segmentation
The market is segmented by application into screening, susceptibility analysis, diagnostic, prognostic, monitoring, and others, out of which, the diagnostic segment is anticipated to hold a notable share in the market during the forecast period on account of increasing incidences of late diagnosis of chronic diseases, which makes their treatment more complicated and riskier. Early diagnosis can eliminate such critical cases, and improve the success rate of the treatment.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Application |
|
|
End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPredisposition Biomarkers Industry - Regional Synopsis
Regionally, the global predisposition biomarkers market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is poised to account for largest revenue share by 2037, owing to undergoing advanced research and development in the healthcare sector along with innovative clinical experiments, and development of new diagnostic tools. The market in the Asia Pacific is estimated to witness notable growth accounting to the increasing geriatric population, along with increasing cases of various chronic diseases, such as, cancer, hypertension, and diabetes. Moreover, development in the healthcare sector, backed by government initiatives and increasing investment, is anticipated to boost the market growth.
Companies Dominating the Predisposition Biomarkers Landscape
- Siemens Healthcare GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Danaher Corporation
- Biomarker Technologies, Inc.
- Almac Group Limited
- Myriad Genetics, Inc.
- F. Hoffmann-La Roche Ltd
- Epigenomics AG
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- QIAGEN GmbH
In the News
· March 02, 2021: Myriad Genetics to join hands with Intermountain Precision Genomics to produce germline genetic testing services.
Author Credits: Radhika Pawar
- Report ID: 3090
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
